Table 1.
Baseline demographic and clinical characteristics.
Fig 1.
All eligible patients received vedolizumab as induction and maintenance therapy. Outcome assessments were performed at weeks 14 and 54. In total, 11 patients were included for analysis at week 14 (n = 7 with clinical remission, n = 4 without clinical remission) and 9 patients at week 54 (n = 6 with clinical remission, n = 3 without clinical remission).
Fig 2.
Complete Mayo score and fecal calprotectin levels.
Box plots showing the complete Mayo score and fecal calprotectin levels at baseline, week 14, and week 54 in patients with and without clinical remission at week 54. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. Graphs are based on observed data; patients with missing data were excluded from analyses. *p < 0.05. Q, quartile.
Fig 3.
Vedolizumab concentrations in serum and colorectal tissue.
Box plots showing the concentrations of vedolizumab in serum and colorectal tissue at week 14 and week 54/discontinuation in patients with and without clinical remission. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. Q, quartile.
Fig 4.
Median (IQR) α4β7 integrin saturation on lymphocytes in blood and colorectal tissue (%) at week 14 and week 54/discontinuation in patients with and without clinical remission. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. IQR, interquartile range; Q, quartile.
Fig 5.
T cell immunophenotype proportions after vedolizumab treatment.
Comparisons of median T cell immunophenotype proportions (%) after vedolizumab treatment at week 14 and week 54 between patients with and without clinical remission. Proportions were compared in patients with and without clinical remission using the Mann-Whitney U-test. Treg cells could not be measured in tissue because of low quantities. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. *p < 0.05. Q, quartile.
Fig 6.
T cell immunophenotype proportions at baseline.
Comparisons of T cell immunophenotype proportions (%) at baseline in patients with and without week 54 clinical remission. Proportions were compared in patients with and without clinical remission using the Mann-Whitney U-test. Treg cells could not be measured in tissue because of low quantities. In the box plots, horizontal lines depict the Q1–Q3 range and median, and whiskers represent the minimum and maximum values. *p < 0.05. Q, quartile.